Welcome to our dedicated page for SIGA TECHNOLOGIES SEC filings (Ticker: SIGA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SIGA Technologies Inc. filings document the formal disclosure record for a commercial-stage pharmaceutical company whose business is centered on TPOXX (tecovirimat) and infectious-disease countermeasures for orthopoxviruses. Recent Form 8-K reports furnish operating results and business updates tied to oral and IV TPOXX revenue, product deliveries, research and development revenue, procurement activity, and BARDA-supported development work.
The filing record also includes special cash dividend disclosures and definitive proxy materials for annual meeting matters. These documents cover common-stock capital actions, board and governance proposals, stockholder voting procedures, earnings press release exhibits, and other Exchange Act reporting events.
SIGA Technologies reported Q2 2026 revenue of $41.0 million, down from $81.1 million a year earlier, as U.S. government purchases of oral TPOXX slowed and sales shifted toward IV TPOXX and new international orders. Net income was $12.5 million versus $35.5 million, with lower cost of sales and SG&A partly offsetting the revenue decline.
For the first half of 2026, revenue was $47.2 million and net income $9.0 million. Cash and cash equivalents were $117.6 million, and a special cash dividend of $0.60 per share (about $43.9 million) was paid. Results remain concentrated in government contracts, notably the BARDA agreement providing up to approximately $630 million of potential payments. Management notes an effective tax rate influenced by currently forecasted full‑year losses based on orders received to date.
SIGA Technologies reported Q2 and first-half 2026 results, with continued TPOXX sales but lower revenue and profit versus 2025. For the three months ended June 30, 2026, total revenues were $41.0 million and net income $12.5 million, compared with $81.1 million and $35.5 million a year earlier; diluted EPS was $0.17.
The company delivered approximately $37 million of TPOXX in Q2, including $24 million of IV TPOXX to the U.S. strategic national stockpile and $13 million of oral TPOXX to two international customers. As of June 30, 2026, cash and cash equivalents were $117,584,444, total assets $175,736,786, and stockholders’ equity $165,290,635.
SIGA Technologies director Joseph W. Marshall III reported several equity compensation-related moves. On June 9, 2026, he exercised 24,116 restricted stock units (RSUs) into common stock at a conversion price of $0.00 per share, and 7,235 common shares were disposed of to the issuer at $4.39 per share. Following these transactions, he directly held 246,523 shares of common stock. He also received a new grant of 34,169 RSUs, which fully vest on the date of SIGA’s 2027 annual meeting of stockholders; up to 10,251 of these RSUs may be settled in cash at the Board’s discretion.
SIGA Technologies director John M. Keane reported several equity compensation-related transactions. On June 9, 2026, he exercised 24,116 restricted stock units into common stock at a stated price of $0.00 per share and then returned 7,235 common shares to the issuer at $4.39 per share in a disposition to the company.
He also received a new award of 34,169 restricted stock units, which represent contingent rights to receive SIGA common stock on a one-for-one basis, with a portion eligible for cash settlement at the Board’s discretion. Following these transactions, Keane directly holds 16,881 common shares and maintains a new RSU position scheduled to fully vest at the Company’s 2027 annual meeting of stockholders.
SIGA Technologies director Harold Eugene Ford Jr. reported several equity compensation moves on June 9, 2026. He disposed of 7,235 shares of common stock back to the issuer at $4.39 per share, a disposition categorized as a return of shares to the company rather than an open-market sale.
On the same date, he exercised derivative awards to acquire 24,116 shares of common stock at a stated price of $0.00 per share, converting previously granted restricted stock units into shares. Following these transactions, he held 47,538 shares of common stock directly.
Ford also received a new grant of 34,169 restricted stock units (RSUs), each representing a contingent right to receive one share of SIGA common stock. According to the footnotes, these RSUs fully vest on the date of the company’s 2027 annual meeting of stockholders, and up to 10,251 RSUs under this award may be settled in cash rather than shares at the board’s discretion.
SIGA Technologies director Holly L. Phillips reported several equity compensation transactions in company stock. On June 9, 2026, she disposed of 7,235 shares of common stock back to the issuer at $4.39 per share and exercised derivative securities to acquire 24,116 common shares at a $0.00 exercise price. She also received a grant of 34,169 restricted stock units (RSUs) and exercised 24,116 RSUs into common stock, with the RSUs representing contingent rights to receive SIGA common shares on a one-for-one basis.
SIGA Technologies Inc director Julian Nemirovsky reported routine equity compensation moves. He exercised 24,116 restricted stock units into common shares and returned 7,235 common shares to the issuer at $4.39 per share. He also received a grant of 34,169 new RSUs that vest at the 2027 annual meeting. Following these transactions, he holds 80,989 common shares directly and 34,169 RSUs tied one-for-one to common stock, with part of the RSUs designed for cash settlement to address tax obligations.
SIGA Technologies director Jaymie A. Durnan reported routine equity compensation activity and a small disposition to the company. On June 9, 2026, Durnan exercised derivative awards to acquire 24,116 shares of common stock and, in a separate transaction, disposed of 7,235 shares back to the issuer at $4.39 per share. Following these transactions, Durnan directly owned 95,989 shares of common stock. In addition, Durnan received a grant of 34,169 restricted stock units (RSUs), which represent contingent rights to receive common stock on a one-for-one basis and fully vest on the date of SIGA’s 2027 annual meeting of stockholders, with up to 10,251 of these RSUs expected to be settled in cash value under the Board compensation program.
SIGA Technologies director Gary J. Nabel reported several equity compensation transactions. On June 9, 2026, he exercised 24,116 restricted stock units into the same number of common shares at a stated price of $0.00 per share and then disposed of 7,235 common shares back to the company at $4.39 per share in a transaction classified as a disposition to the issuer. Following these moves, he directly held 73,754 shares of common stock. Nabel also reported a prior grant of 34,169 restricted stock units, which vest on the date of the company’s 2027 annual meeting of stockholders, with footnotes noting that a portion of these RSUs may be cash-settled to address tax obligations.
SIGA Technologies, Inc. reported the results of its 2026 annual stockholders meeting. Stockholders approved an amendment to the Amended and Restated 2010 Stock Incentive Plan, increasing the maximum shares of common stock authorized for issuance under the plan from 8,500,000 to 15,000,000, an increase of 6,500,000 shares.
Shareholders representing 62,436,105 shares, or 87.05% of shares outstanding as of April 17, 2026, were present or represented by proxy. They elected eight directors, ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026, and approved a non-binding advisory resolution on executive compensation.